Genomic correlates of indolent neuroblastoma, such as somatic alterations in the ATRX gene or activation of the alternative lengthening of telomeres (ALT) mechanism, have been defined36–41, but we have been unsuccessful at leveraging these discoveries into more precise therapies. The gene discussed is ATRX; the disease is neuroblastoma.